DOI:
10.1055/s-00000030
Der Klinikarzt
LinksClose Window
References
Hochhaus H et al.
Nilotinib Shows Sustained Benefits Compared With Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 4-Year Follow-Up.
EHA 2013; Abstract #P712
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.